Array将重获诺华抗癌药Binimetinib开发和营销权

　　本周三，诺华与Array Biopharma公司签署协议宣布，Array将重新获得其抗癌药物Binimetinib的开发和营销权利。

　　Array重购Binimetinib将有可能促其获得GSK的抗癌药Mekinist：今年四月诺华宣布与葛兰素史克（GSK）进行一项业务重组，GSK的抗癌药业务被列入其中，一旦明年年初重组完成，诺华将从GSK获得其近期被核准的MEK抑制剂Mekinist，而Binimetinib也是一种MEK抑制剂，诺华将有必要把Mekinist转让给艾瑞。

　　诺华将支付给Array的8500万美元作为对Binimetinib的全球开发和营销，根据协议直到诺华与GSK交易完成时结束。诺华也将继续提供一定的资金和后勤支持Binimetinib正在进行的三个III期研究，这些研究招募患有NRAS突变黑色素瘤、BRAF突变黑色素瘤和低度恶性浆液性卵巢癌的患者。三个III期研究中NRAS突变黑色素瘤的研究结果预计可能在2016年年初完成。

　　随着Binimetinib的回归，Array将转向启动投入全部资金的治疗复发/难治性多发性骨髓瘤的filanesib三期研究，这有可能于2015年上半年开始，接近于诺华交易的完成。

以下为原文：

　　Array Biopharma (ARRY) is regaining full development and marketing rights to its experimental cancer drug binimetinib from Novartis (NVS) , according to an agreement between the two companies announced Wednesday.

　　The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline (GSK) which included the acquisition of Glaxo's cancer drug business. Once that deal closes early next year, Novartis will own Glaxo's recently approved MEK inhibitor Mekinist. Binimetinib is also a MEK inhibitor, which necessitated Novartis returning the drug to Array.

　　Array will receive $85 million from Novartis to go along with worldwide development and marketing rights to binimetinib, according to term of the new agreement, which will close when the Novartis-Glaxo deal is fully consumated. Novartis will also continue to provide some financial and logistical support to three ongoing, phase III studies of binimetinib. These studies are enrolling patients with NRAS-mutant melanoma, BRAF-mutant melanoma and low-grade serous ovarian cancer.

　　Of the three phase III studies, results from the NRAS-mutant melanoma study are expected first, likely in early 2016.

　　With binimetinib back in house, Array will turn to starting a phase III study its wholly owned asset filanesib in relapsed/refractory multiple myeloma, which could start in the first half of 2015, pending the close of the Novartis agreement. This study will compare filanesib plus Amgen's(AMGN) Kyprolis against Kyprolis and a placebo.

　　Array finished the third quarter with $111 million in cash.